Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.63 USD | +0.16% | -0.05% | -2.66% |
Mar. 20 | Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT |
Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.66% | 1.69B | C | ||
-11.57% | 7.5B | B- | ||
+2.98% | 5.48B | B | ||
+0.98% | 4.61B | C | ||
+5.18% | 4.47B | C | ||
-50.82% | 3.28B | D+ | ||
+11.23% | 2.71B | - | - | |
-16.38% | 2.02B | B- | ||
-10.84% | 1.74B | D+ | ||
-4.35% | 1.48B | - | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYGN Stock
- Ratings Myriad Genetics, Inc.